Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06849219
PHASE4

Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia

Sponsor: Jinnah Postgraduate Medical Centre

View on ClinicalTrials.gov

Summary

Trigeminal neuralgia is a debilitating neurological condition, affecting quality of life in most affected patients. Carbamazepine has traditionally been used for the management of this condition, but it has a moderate effectiveness and a poor side-effect profile. Oxcarbazepine is more tolerable, and has a more favorable side-effect profile. This study aims to compare the effectiveness of oxcarbazepine and carbamazepine in the management of this condition, for improved prescription practices in the future.

Official title: Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia in Patients Presenting in Outpatient Department of Neurology in Jinnah Postgraduate Medical Centre

Key Details

Gender

All

Age Range

25 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

122

Start Date

2024-09-21

Completion Date

2025-03-21

Last Updated

2025-03-04

Healthy Volunteers

No

Interventions

DRUG

Oxcarbazepine

Oxcarbazepine will be started at a dose of 150 mg BD, and follow-up will be done every month. Dose will be titrated up if minimal pain relief, to a maximum dose of 1800 mg per day.

DRUG

Carbamazepine

Carbamazepine will be started at a dose of 100 mg BD, and follow-up will be done every month. Dose will be titrated up if minimal pain relief, to a maximum dose of 1200 mg per day.

Locations (1)

Jinnah Postgraduate Medical Centre

Karachi, Sindh, Pakistan